Discovery and use of molecular & genomics-based diagnostic markers for acute & chronic disease management. • Development and Execution of operational, business, financial, and technical plans in preparation for product and service launch efforts. • Evaluation of potential novel embodiments of intellectual property. •

• Founding leader establishing on-premises Production and R&D operations for multiple NGS-based products at new location supporting over 100 team members.• Identified, recruited, and managed licensed and unlicensed team members across various disciplines (Bioinformatics, Software Engineering, IT infrastructure & Laboratory) required for production technology operations• Negotiated with key Business Unit leaders to converge on optimal path validation and deployment of regulated testing platform.• Negotiated with technology and automation partners for optimal deployment and transparency. • Worked closely with key stakeholders (R&D, HR, BD, Supply Chain Management, Finance, Facilities, Legal & Regulatory) to renovate, equip, qualify and validate new laboratory & offices

• Member of founding leadership team addressing global healthcare concern through cutting-edge technology..• Identified, recruited, and managed Operations, R&D and Data Infrastructure (ML/AI, Bioinformatics, Software Engineering & IT infrastructure) teams.• Lead efforts to equip and operationalize cutting edge Life Sciences Laboratories.• Worked closely with key stakeholders (Finance, Facilities, Legal & Regulatory) to enable new operational area (Life Sciences) within the Amazon organization.

• Lead cross-functional team major upgrades (mechanical & software) upgrades to over 3,000 RUO (NextSeq) and FDA-cleared (NextSeqDx) NGS instruments across over 1,000 customer locations.• Initiated communication channels & venues to improve customer representation.• Managed multi-site & internal efforts with critical resources located in Asia, Europe and US.• Negotiated with key Business Unit leaders to converge on optimal changes to the platform.• Coordinated platform extension activities including design change, development, verification, and validation to deliver new applications and/or performance/robustness enhancements

• Assembled and lead cross-functional team that produced over 40,000 human and 6,000 microbiome genomes in 3 years.• Participated in the generation and analysis of both Germline and Somatic datasets for assessment of role in oncology, cardiovascular, immunological and metabolic disorders.• Recruited and managed team members in Operations, Technical Development, Quality & Materials Management areas.• Lead integrated team in development of customized scalable NGS-based workflows including Specimen stabilization (human & microbiome), Sample extraction (DNA & RNA), WGS (PCR & PCR-Free), WES (Whole Exome and Disease-Specific Enrichment Panels), RNASeq (Whole transcriptome and Disease-Specific Enrichment Panels)• Best in class operational performance with over 95% “first pass” acceptance (WGS mean coverage: 30x) in production testing and over 90% operational availability for key production line equipment • Established and managed development & production "farm" that included 8 NovaSeq6000, 24 HiSeqX, 6 HiSeq4000, 2 PacBio RS II as well as multiple automated liquid handling platforms (e.g. Hamilton & Tecan)• Managed operational OpEx budget of > $30M/yr and CapEx infrastructure budget > $30M• Member of integrated team guiding development, deployment and utilization of computational NGS pipelines and tools commonly employed in the detection and annotation of germline and somatic variants (e.g. Aspera, HAS, BWA, GATK & Picard).• Worked closely with key stakeholders (Finance, Facilities, IT, Security, Commercial & Regulatory) to enable safe, robust, responsible, compliant and scalable operations.• Lead integrated team enabling real-time monitoring Key Performance Indicators (KPIs).• Developed Cost of Goods and Services (CoGS) models for all production deliverables.• Participated in the definition and development regulatory (CLIA, CAP & QSR) strategy

• Define strategic and tactical goals for clinical sequencing at the Broad.• Developed and managed relationships between the Broad and clinical partners.• Establish regular forums for communication between clinical investigators and Broad scientists.• Report on progress, risks, and opportunities to the Board of Managers and/or Board of Directors.• Drive the development of specific clinical sequencing products, specifically setting specifications for genomic target, sets of genes, coverage required, or data type (DNA or RNA sequence data).• Monitor competitive landscape to define opportunities for new tests or markets.• Participated in the development of external facing marketing & sales collateral.• Assisted in elaboration of CLIA/CAP/QSR-compliant quality system.

• Directed all DNA & RNA – based research/development• Lead effort to identify and secure key talent to establish Molecular Genetics Team• Managed large discovery and validation screens for non – coding RNAs predictive of CVD risk• Initiated & lead analytical validation of NGS – based Cardiovascular Disease Genetics program• Initiated & lead NGS – based software development program• Oversaw validation of equipment, testing, outcomes and results – reporting for twenty – three (23) production tests successfully transferred to clinical laboratory• Assembled analytic and software validation packages for CLIA – certification.• Provide technical input to Laboratory Manager and Laboratory Director• Represented Aviir at national meetings• Developed network of leading academic researchers in support of Cardiovascular Disease Genetics program• Participated in the development of client – facing sales collateral

• Directed all DNA & RNA – based research/development• Lead effort to identify and secure key talent to establish Molecular Genetics Team• Managed large discovery and validation screens for non – coding RNAs predictive of CVD risk• Initiated & lead analytical validation of NGS – based Cardiovascular Disease Genetics program• Initiated & lead NGS – based software development program• Oversaw validation of equipment, testing, outcomes and results – reporting for twenty – three (23) production tests successfully transferred to clinical laboratory• Assembled analytic and software validation packages for CLIA – certification.• Provide technical input to Laboratory Manager and Laboratory Director• Represented Aviir at national meetings• Developed network of leading academic researchers in support of Cardiovascular Disease Genetics program• Participated in the development of client – facing sales collateral

• Directed all laboratory research/development and clinical trials operations• Serve as expert technology reference to Clinical Laboratory• Oversaw validation of equipment, testing, outcomes and results – reporting for all feasibility and validations transferred to clinical laboratory and clinical trials• Provide technical input to Laboratory Manager and Laboratory Director• Established pricing schedules for a variety of standard (eg. IHC) and esoteric (eg. Sequencing, qPCR, LCM) service offerings• Participated in the development of client – facing sales collateral• Lead meetings with clients to set project goals and specification as well as for interim and final data analysis

• Directed all laboratory research and clinical trials operations and staff• Facility capacity 100,000 tests/arrays per year• Initiated & managed day to day relationship with pioneering Direct – to – Consumer (DTC) genetics testing company• Developed and managed secure data analysis and transfer processes• Oversaw validation of equipment, testing, outcomes and results – reporting for all feasibility and validations transferred to clinical laboratory and clinical trials• Train and supervise personnel associated with proprietary techniques and processes• Performed and/or direct all professional scientific aspects of Gene Expression and Genotyping • Reviewed, refined and approved technical execution of data in feasibility and development• Performed and/or directed analysis of data• Rendered accurate diagnoses and report results to clinical laboratory, clinical trials clients• Directed scientific communication with active and potential clients• Discussed cases and answered questions related to analysis and processes as necessary• Ensured approval for of all testing/analyses requested by clinical lab• Ensured appropriateness of requests for analyses• Directed the scientific research and early technology development activities of the Laboratory• Provided expert advice on new products, concepts and projects• Critically evaluated complex data and (co)author reports and papers• Developed, processed and protected intellectual property in all domains of activity• Supervised activities and training of 7 laboratory personnel• Served as technical expert for all aspects of clinical laboratory facilities design and maintenance

• Developed assays to elucidate mechanisms underlying the negative regulation of FoxO – related transcription factors by the Phosphatidylinositol – 3 kinase (PI – 3 kinase) – activated signal transduction pathway.• Generated & characterized lines of 'ʹknock – out'ʹ mice lacking Foxo1, Foxo3, & Mllt7 loci.• Isolated & characterized orthologs of the human forkhead – related transcription factor, FoxO1, expressed during development in mouse, chick, & zebrafish.• Identified potential in vivo transcriptional targets of FKHR1 via mRNA profiling.• Established chromosomal location of mouse FoxO – related loci through Inter – Specific Backcross Maps• Identification and mapping of heritable traits using genetic markers (VNTR, RLFP, and SNP).

• Developed project to identify & assess a requirement for orthologs of the MAP kinases ERK1 & 2 expressed during retinal development in Drosophila melanogaster.• Determined that Drosophila MAP kinase is encoded by the rolled (rl) locus.• Integrated Drosophila rolled/MAP kinase into the sevenless (sev) signal transduction pathway regulating the development of the R7 photoreceptor cell.